EPISODE · Jul 14, 2026 · 26 MIN
ASH Annual Meeting
from Oncology Times - OncTimes Talk
Peter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); and Michael Hallek and Tadeusz Robak (on improved benefits for CLL patients with rituximab added to standard chemotherapy). Offering perspective are Kenneth Kaushansky, Linda Burns, and George Canellos.
NOW PLAYING
ASH Annual Meeting
0:00
26:57
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Oncology Times - OncTimes Talk?
This episode is 26 minutes long.
When was this Oncology Times - OncTimes Talk episode published?
This episode was published on July 14, 2026.
What is this episode about?
Peter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); and Michael Hallek...
Can I download this Oncology Times - OncTimes Talk episode?
Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!